Damora Therapeutics (DMRA) Gains from Investment Securities (2020 - 2026)
Damora Therapeutics posted quarterly Gains from Investment Securities of $4.0 million for Q1 2026, up 707.48% on a QoQ basis from -$666000.0 in Q4 2025.
Damora Therapeutics (DMRA) has 7 years of Gains from Investment Securities data on file, last reported at $4.0 million in Q1 2026.
- For the quarter ending Q1 2026, Gains from Investment Securities changed N/A year-over-year to $4.0 million; the trailing twelve-month figure through Mar 2026 stood at $4.0 million (changed N/A YoY), and the FY2025 full-year result was $983375.0, up 342.8% from the prior year.
- Gains from Investment Securities for Q1 2026 stood at $4.0 million, up from -$666000.0 in the prior quarter.
- Across five years, Gains from Investment Securities topped out at $7.7 million in Q2 2023 and bottomed at -$1.9 million in Q4 2024.
- The 5-year median for Gains from Investment Securities is $425489.5 (2022), against an average of $1.6 million.
- The widest annual swing landed in 2023, when Gains from Investment Securities surged 357.95%; it then sank 2424.68% in 2024.
- A 5-year view of Gains from Investment Securities shows it stood at -$942000.0 in 2022, then soared by 91.83% to -$77000.0 in 2023, then tumbled by 2424.68% to -$1.9 million in 2024, then soared by 65.74% to -$666000.0 in 2025, then soared by 707.48% to $4.0 million in 2026.
- The last three Gains from Investment Securities figures came in at $4.0 million (Q1 2026), -$666000.0 (Q4 2025), and $241132.0 (Q2 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,216,509.61 Bn | 1,216,509.61 Bn | - |
| 2 | Alterity Therapeutics | 764,224.41 Bn | 764,224.38 Bn | - |
| 3 | Legend Biotech | 2,716.00 Bn | 2,715.71 Bn | 242.10 Mn |
| 4 | Nanobiotix | 2,248.83 Bn | 2,248.77 Bn | - |
| 5 | Akari Therapeutics | 1,951.18 Bn | 1,951.17 Bn | - |
| 6 | Vertex Pharmaceuticals | 113.69 Bn | 106.44 Bn | 2.59 Bn |
| 7 | Evaxion A | 64.16 Bn | 64.14 Bn | - |
| 8 | Regeneron Pharmaceuticals | 63.94 Bn | 55.18 Bn | 3.31 Bn |
| 9 | Alnylam Pharmaceuticals | 40.13 Bn | 37.12 Bn | 959.66 Mn |
| 10 | Damora Therapeutics | 853.36 Mn | 650.97 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 4.05 Mn |
| Mar 31, 2026 | 4.05 Mn |
| Dec 31, 2025 | -666,000.00 |
| Dec 31, 2025 | -666,000.00 |
| Jun 30, 2025 | 241,132.00 |
| Jun 30, 2025 | 241,132.00 |
| Dec 31, 2024 | -1.94 Mn |
| Dec 31, 2024 | -1.94 Mn |
| Sep 30, 2024 | 182,205.00 |
| Sep 30, 2024 | 182,205.00 |
| Jun 30, 2024 | 1.44 Mn |
| Jun 30, 2024 | 1.44 Mn |
| Dec 31, 2023 | -77,000.00 |
| Dec 31, 2023 | -77,000.00 |
| Sep 30, 2023 | 401,979.00 |
| Sep 30, 2023 | 401,979.00 |
| Jun 30, 2023 | 7.67 Mn |
| Jun 30, 2023 | 7.67 Mn |
| Mar 31, 2023 | 7.55 Mn |
| Mar 31, 2023 | 7.55 Mn |
| Dec 31, 2022 | -942,000.00 |
| Dec 31, 2022 | -942,000.00 |
| Sep 30, 2022 | 449,000.00 |
| Sep 30, 2022 | 449,000.00 |
| Jun 30, 2022 | 1.77 Mn |
| Jun 30, 2022 | 1.77 Mn |
| Mar 31, 2022 | 1.65 Mn |
| Mar 31, 2022 | 1.65 Mn |
| Dec 31, 2021 | 663,000.00 |
| Dec 31, 2021 | 663,000.00 |
| Sep 30, 2021 | 409,000.00 |
| Sep 30, 2021 | 409,000.00 |
| Jun 30, 2021 | 409,000.00 |
| Jun 30, 2021 | 409,000.00 |
| Mar 31, 2021 | 936,000.00 |
| Mar 31, 2021 | 936,000.00 |
| Dec 31, 2020 | 41,000.00 |
| Dec 31, 2020 | 41,000.00 |
| Sep 30, 2020 | 420,000.00 |
| Sep 30, 2020 | 420,000.00 |
| Jun 30, 2020 | 252,000.00 |
| Jun 30, 2020 | 252,000.00 |
| Mar 31, 2020 | 304,142.00 |
| Mar 31, 2020 | 304,142.00 |